The goal of the investigators study is to investigate the role of a hormone named Activin A (ActA) in the development of the skeletal muscle atrophy caused by cancer. According to the investigators hypothesis, ActA could be released by the tumor and activate a muscle atrophy gene program. To answer this question, the investigators plan first to compare circulating levels of ActA in cancer patients with and without cachexia. In a second step, the investigators would like to assess whether ActA circulating levels are predictive for the development of cachexia and short survival.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
150
blood tests and muscular biopsies
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Circulating Activin A level
Time frame: 2 years
Dietary assessment measured by SNAQ score and 3-Day intake
Time frame: 2 years
Body mass index
Time frame: 2 years
Mid arm muscle circumference calculated by the triceps skinfold and the mid arm circumference
Time frame: 2 years
Body composition measured by bioimpedance
Time frame: 2 years
Muscle strength as measured by grip strength
Time frame: 2 years
Quality of life as assessed using the QLQ-C30
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.